December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KALA BIO, Inc. - Common Stock (NQ:KALA)

0.1929 +0.0018 (+0.94%)
Streaming Delayed Price Updated: 9:51 AM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KALA BIO, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024 ↗
KALA stock results show that Kala Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Kala Bio: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction ↗
Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects. 
Via Stocktwits
News headline image
Dow Drops More Than 400 Points After CPI Data ↗
This morning's hotter-than-expected CPI data sent the market reeling, after the annual inflation rate rose to 3% and the 12-month core inflation rate rose to 3.3%. 
Via Talk Markets
Topics Economy Stocks Stocks / Equities
News headline image
KALA BIO Announces Chief Executive Officer Transition
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces $10,750,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Announces $12,500,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA Stock Earnings: Kala Pharmaceuticals Misses EPS for Q1 2024 ↗
KALA stock results show that Kala Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023 ↗
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.